drugset / Trial / NCT04834986
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
Timeline
- Start
- 2021-04-30
- Primary completion
- 2022-04-30
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg/kg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |